Buy Tirzepatide for Sale
Tirzepatide is a polypeptide that combines the actions of two different hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It has been shown to improve blood sugar control and promote weight loss in clinical studies.
Research shows that Tirzepatide can improve insulin sensitivity, reduce appetite and improve lipid metabolism. It has also been found to lower levels of low-density lipoprotein or ‘bad’ cholesterol and elevate high-density lipoprotein or ‘good’ cholesterol levels.
What is Tirzepatide?
Tirzepatide is a synthetic peptide analog of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). While GIP plays a role in lipid metabolism and the development of obesity, GLP-1 regulates insulin secretion in the body.
Tirzepatide was originally developed by Eli Lilly, a US pharmaceutical company. It was initially designed for the treatment of type-2 diabetes (T2DM). Tirzepatide is also being examined as a possible treatment for obesity and non-alcoholic fatty liver disease. [R]
Clinical trials have shown that Tirzepatide can improve blood glucose control, reduce body weight, and lower blood pressure in people with type 2 diabetes. It has also been found to reduce feelings of hunger, lower insulin levels, and improve insulin sensitivity. [R]
Additionally, this GLP-1 receptor agonist has been shown to elevate the concentrations of HDL or ‘good’ cholesterol and lower the levels of LDL or ‘bad’ cholesterol. Another observed effect of Tirzepatide includes improvement in gastrointestinal tolerance. [R]
How Does Tirzepatide Work?
Tirzepatide works by mimicking the actions of gastric inhibitory peptide and glucagon-like peptide. This dual mechanism of action makes Tirzepatide more effective than strict GLP-1 agonists, which only work on one hormone and not the other. [R]
Gastric inhibitory polypeptide is a hormone produced by cells within the intestine. It inhibits lipolysis (fat breakdown) and encourages lipogenesis (fat formation). Tirzepatide binds to the GIP receptor to stimulate insulin release and inhibit gastric acid secretion.
Glucagon-like peptide receptors are found in various regions of the central nervous system, including the brain. Activation of GLP-1R has been shown to increase insulin synthesis and insulin release. Additionally, the stimulation of GLP-1R leads to reduced appetite.
Tirzepatide has been the subject of numerous clinical studies. These investigations have examined its effects on body weight, obesity, diabetes, insulin secretion, and body fat percentage. Here are the key findings obtained from these studies:
Tirzepatide and Obesity
Multiple clinical studies have shown that Tirzepatide stimulates weight loss.
A phase 3 clinical trial reported that type-2 diabetes patients taking Tirzepatide lost up to 52 lbs within 72 weeks of treatment. The most commonly reported adverse events were mild to moderate in severity. They were all gastrointestinal-related. [R]
Similar results were obtained in a follow-up study. Published in 2023, the study reported that participants with obesity and type-2 diabetes lost up to 32.4 lbs after taking Tirzepatide for 18 months. At least 81.6% of participants lost 5.6% of body weight. [R]
A 3rd study examined whether Tirzepatide or Semaglutide (an anti-diabetic medication) provides better value for money when used for weight reduction in patients with T2D. It found that the total cost of weight reduction was lower for Tirzepatide. [R]
Tirzepatide and Diabetes
According to a 2022 study, Tirzepatide treatment for 40 weeks successfully lowered blood sugar levels in patients with type-2 diabetes. Three different doses of this GLP-1 receptor agonist were examined and all three had beneficial effects on blood sugar levels. [R]
Another 2022 study reported that Tirzepatide was more effective than Semaglutide in reducing glucose excursions in patients with type-2 diabetes. This GLP-1 receptor agonist was also more effective in enhancing insulin secretion and insulin sensitivity. [R]
Tirzepatide and Heart Health
A recent study reports that Tirzepatide reduces serum triglyceride concentrations in patients with type-2 diabetes at high cardiovascular risk. High levels of triglycerides may contribute to the hardening of the artery walls, increasing your risk of heart disease. [R]
In the same study, Tirzepatide was found to dose-dependently decrease the levels of low-density lipoprotein or ‘bad’ cholesterol. Additionally, this GLP-1 receptor agonist enhanced the levels of high-density lipoprotein or ‘good’ cholesterol. [R]
Tirzepatide and Appetite
According to a secondary analysis of a randomized, double-blind, parallel-arm study, Tirzepatide treatment significantly reduced appetite versus placebo. The study whose results were analyzed was conducted on people with type-2 diabetes. [R]
Research has shown that Tirzepatide reduces food intake by imitating GLP-1, a hormone that regulates appetite in the body. GLP-1 reduces your food appetite by delaying gastric emptying and gut motility (movement of mood through and out of the body). [R]
Tirzepatide and Blood Pressure
Hypertension is a common comorbidity of type 2 diabetes (T2D) and is twice as prevalent in people with T2D compared with those without T2D.
A clinical review of 5 human studies reports that Tirzepatide treatment reduced systolic blood pressure in patients with T2D. It also noted that Tirzepatide-induced blood pressure reduction was primarily mediated through weight loss. [R]
Tirzepatide and Non-Alcoholic Fatty Liver Disease
NAFLD is a serious condition caused by a high accumulation of fat in the liver cells that isn’t caused by excessive alcohol consumption. It is estimated to affect up to 25% of the adult population in the US.
Results from a post hoc analysis show that higher doses of Tirzepatide significantly reduced NAFLD-related biomarkers in people with T2D. The participants also experienced increased levels of adiponectin, a hormone that exerts a protective effect against NAFLD. [R]
Another study reported that people with T2D taking Tirzepatide (15 mg) experienced a 47.11% relative reduction in liver fat. This is significant as excessive liver fat can lead to NAFLD. [R]
Frequently Asked Questions
What is the half-life of Tirzepatide?
Tirzepatide has a half-life of approximately five days. This means it takes the bloodstream up to 30 days to eliminate this drug from the body.
What does Tirzepatide do?
Various clinical studies have shown that Tirzepatide stimulates weight loss and lowers systolic blood pressure and blood glucose levels in people with type-2 diabetes. It has also been found to reduce appetite and the concentration of liver fat.
How does Tirzepatide work for weight loss?
Tirzepatide stimulates weight loss by mimicking the actions of glucagon-like peptide 1 (GLP-1). It delays gastric emptying and slows the rate at which the food passes through the digestive tract.
Is Tirzepatide harmful to the kidneys?
According to clinical studies conducted to date, Tirzepatide exerts no effects on kidneys.
Where to Buy Tirzepatide for Sale?
ResearchChems.org is the best place to buy Tirzepatide online.
We have been around since 2023, supplying the highest-quality research chemicals money can buy. Our products come with a 100% satisfaction guarantee, fast shipping, and great customer service to turn every customer into a repeat customer.
Tirzepatide is a synthetic peptide that acts as a dual receptor agonist of GIP and GLP-1 in the body. In clinical studies, it has been shown to induce significant weight loss, improve glycemic control and reduce fat intake in people with type-2 diabetes.
ResearchChems.org sells Tirzepatide for laboratory and research use only.